Price
CHART BY
Frequently asked questions
What is Catalyst Pharms's market capitalization?
The market capitalization of Catalyst Pharms is $3.85B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Catalyst Pharms's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Catalyst Pharms is 18.10. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Catalyst Pharms?
Catalyst Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is 1.74. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Catalyst Pharms's stock?
Currently, 1 analysts cover Catalyst Pharms's stock, with a consensus target price of $31.50. Analyst ratings provide insights into the stock's expected performance.
What is Catalyst Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, Catalyst Pharms reported a revenue of $596.96M.
What is the EBITDA for Catalyst Pharms?
Catalyst Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $306.20M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Catalyst Pharms?
Catalyst Pharms has a free cash flow of $208.13M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Catalyst Pharms have, and what sector and industry does it belong to?
Catalyst Pharms employs approximately 182 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Catalyst Pharms's shares?
The free float of Catalyst Pharms is 111.65M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.85B
- EPS (TTM)
- 1.74
- Free Float
- 111.65M
- P/E ratio (TTM)
- 18.10
- Revenue (TTM)
- $596.96M
- EBITDA (TTM)
- $306.20M
- Free Cashflow (TTM)
- $208.13M
Analyst Ratings
The price target is $31.50 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
- Employees
- 182
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- CPRX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet